NSEAnalysts/Institutional Investor Meet/Con. Call Updates7 Aug 2026 · 7 Aug 2026, 02:49 pm
Analysts/Institutional Investor Meet/Con. Call Updates
Glenmark Pharmaceuticals Limited · GLENMARK
✦ AI Summary
Glenmark Pharmaceuticals has informed the Exchange about the schedule of analyst/institutional investor meetings to be conducted in August and September 2026.
Analysis Scores
Earnings Impact0/10
Growth Catalyst0/10
Governance Concern0/10
Regulatory Risk0/10
Balance Sheet Risk0/10
Liquidity Impact0/10
Market Sentiment0/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Glenmark Pharmaceuticals Limited has informed the Exchange about Schedule of meet
Attachments (1)
📄pdf
Download →
GLENMARK_07082026144853_SE_Investor_Meet_Signed.pdf
View document text
August 7, 2026
To, To,
National Stock Exchange of India Limited, BSE Limited,
“Exchange Plaza”, Corporate Relationship Department,
5th Floor, Plot No. C/1, G Block, 2nd Floor, New Trading Ring,
Bandra- Kurla Complex, Bandra (East), Mumbai P.J. Towers, Dalal Street,
– 400 051 Mumbai – 400 001
Scrip Name: GLENMARK Scrip Code: 532296
ISIN: INE935A01035 ISIN: INE935A01035
Our Reference No. 43/26-27 Our Reference No. 43/26-27
Dear Sir,
Sub: Intimation of Schedule of Analyst / Institutional Investor Meetings
Pursuant to the relevant provisions of the SEBI (Listing Obligations and Disclosure Requirements)
Regulations, 2015, we would like to inform details of the Analyst / Institutional Investor meetings to
be conducted as under:
Group /
Analyst/Institutional Type of
Date Venue One-on-
Investors/Event Meeting
12-08-2026 Emkay Confluence 2026 Mumbai Physical Both
17-08-2026 Motilal Oswal 22nd Annual Investor Mumbai Physical Both
Conference 2026
01-09-2026 Elara India Dialogue 2026 Mumbai Physical Both
17-09-2026 Kotak Healthcare Forum Mumbai Physical Both
The company will not be disclosing any Unpublished Price Sensitive Information (UPSI) at these
meetings. The schedule of the above-mentioned meetings is subject to change due to exigencies on
the part of Investor / Company. We request you to take this intimation on record.
Thanking you.
Yours faithfully,
For Glenmark Pharmaceuticals Limited
Rashmi Khandelwal
Company Secretary & Compliance Officer
ACS – 28839
Glenmark Pharmaceuticals Limited
Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099
T: 91 22 4018 9999 F: 91 22 4018 9988 CIN No: L24299MH1977PLC019982 W: www.glenmarkpharma.com
Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com